Menu

Phase 1 Capabilities

  • Nine Phase 1 capable sites with 14 locations in the United States and Canada with 23 Principal Investigators.
  • Collectively conducted 55 Phase 1 trials - 21 were first-in human trials.
  • Overnight capabilities in 8 locations with 107 beds combined. Facilities range from 4,000 to 17,000 sf.
  • On-site pharmacies at 6 sites; PBMC capabilities at 5 sites.
  • Over 2.8 million patients in collective databases; diversity recruitment in Hispanic, Asian, and Black communities.

    Phase 1 Regulatory Audits: FDA, Health Canada
    Memberships: Verified Clinical Trials (VCT)

Phase 1 Partner Locations

United States
Austin, TX
Columbus, OH
Hialeah, FL
Ft. Worth, TX
Los Angeles, CA
New Orleans, LA (2)
Omaha, NE
Oxnard, CA
Sacramento, CA
San Antonio, TX (2)
Winter Park, FL

Canada
Toronto, ON

Phase 1 Testing/Equipment

  • Biosafety Cabinets (Class II, A2)
  • Crash carts, Difibrillators, ECGs
  • Echocardiograms, X-rays, MRIs
  • FibroScans®
  • Glucose Clamping
  • Glucose and Lactate Analyzer
  • Infusion Pumps
  • Insulin Challenge
  • Laminar Fume Hoods (Sterile)
  • Nerve Conduction Testing
  • PBMC Processing
  • PK/PD Capabilities
  • Patient Monitoring Devices
  • Point-of-Care Blood Analyzers
  • RT-PCR Machines
  • Sleep Labs
  • Telemetry Machines

Phase 1 Therapeutics

  • Autoimmune/Inflammation
  • Cardiovascular
  • Central Nervous System
  • Dermatology
  • Device
  • Exercise/Nutrition
  • Gastroenterology
  • Healthy Volunteers
  • Infectious Diseases
  • Metabolic/Endocrinology
  • Multiple-Ascending Dose
  • Nephrology
  • Oncology/Hematology
  • Ophthalmalogy
  • Pain Management
  • Pediatrics
  • Psychiatry
  • Pulmonology/Sleep Medicine
  • Single-Ascending Dose
  • Tobacco
  • Toxicology
  • Urology
  • Vaccine
  • Women's Health